Dr. Rubén D Artero Allepuz
Principal Investigator
Research Group on Translational Genomics
Presentation
Dr. Artero is Professor of Genetics at the University of Valencia, where he studied Biochemistry at the Faculty of Biology and obtained his Ph.D. He completed a six-year postdoctoral stay at the Memorial Sloan-Kettering Cancer Center in New York (www.mskcc.org), where he investigated the molecular bases of myogenic differentiation in Drosophila, returning to Spain in 2002 with a contract from the prestigious Ramón y Cajal program of the science and innovation ministry.
His research focuses on the analysis of the pathophysiological mechanisms of Myotonic Dystrophy (DM), Spinal Muscular Atrophy (SMA) and Limb Girdle Muscular Dystrophy (LGMDD2); always from an applied vision of research, covering both the repositioning of drugs, as well as the development of therapeutic oligonucleotides and drug targeting methods, using for this Drosophila, and cell and murine models. His studies on the functions of miRNAs, which contribute to the process of muscle atrophy in the aforementioned diseases and also occurs in cancer-induced cachexia, are of special relevance. He has participated in 75 scientific publications, has been academic editor of the journals PLOS ONE and Scientific Reports, and is a regular contributor to other international journals. He has directed 15 doctoral theses. He maintains national and international collaborations and is part of a group of excellence Prometeo and the Biotecmed University Institute.
On the innovative side, he is an inventor on 19 patents and is co-founder of the spin-off company ARTHEx Biotech, which is developing the first antimiR drug as a therapy for myotonic dystrophy.
Publications
Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice. Bargiela A, Ten-Esteve A, Marti-Bonmati L, Sevilla T, Perez Alonso M, Artero R. Scientific Reports. 2023 Jan 10;13(1):503. doi: 10.1038/s41598-023-27661-w. PMID: 36627397
The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Pascual-Gilabert M, Artero R, Lopez-Castel A. Drug Discovery Today. 2023 Jan 9;28(3):103489. doi: 10.1016/j.drudis.2023.103489. PMID: 36634841
Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model. Januel C, Menduti G, Mamchaoui K, Martinat C, Artero R, Konieczny P, Boido M. Cellular and Molecular Life Sciences. 2022 Jul 22;79(8):441. doi: 10.1007/s00018-022-04450-8. PMID: 35864358
Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model. Overby SJ, Cerro Herreros E, Gonzalez Martinez I, Varela MA, Seoane Miraz D, Jad Y, Raz R, Moller T, Perez Alonso M, Wood MJ, Llamusi B, Artero R. Molecular Therapy. Nucleic Acids. 2022 Feb 10;27:1146-1155. doi: 10.1016/j.omtn.2022.02.003. PMID: 35282418
Defined d-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease. Rapisarda A, Bargiela A, Llamusi B, Pont I, Estrada-Tejedor R, Garcia-Espana E, Artero R, Perez-Alonso M. Scientific Reports. 2021 Sep 30;11(1):19417. doi: 10.1038/s41598-021-98866-0. PMID: 34593893
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Klionsky D, Abdel-Aziz A, Abdelfatah S, et al. Autophagy. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280. PMID: 33634751
Inhibition of autophagy rescues muscle atrophy in a LGMDD2 Drosophila model. Blazquez-Bernal A, Fernandez-Costa JM, Bargiela A, Artero R. FASEB Journal. 2021 Oct;35(10):e21914. doi: 10.1096/fj.202100539RR. PMID: 34547132
Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression. Sabater-Arcis M, Bargiela A, Moreno N, Poyatos-Garcia J, Vilchez J, Artero R. Molecular Therapy-Nucleic Acids. 2021 Aug 19;25:652-667. doi: 10.1016/j.omtn.2021.08.010. PMID: 34589284
miR-7 Restores Phenotypes in Myotonic Dystrophy Muscle Cells by Repressing Hyperactivated Autophagy. Sabater Arcis M, Bargiela Schonbrunn A, Furling D, Artero Allepuz R. Molecular therapy. Nucleic acids. 2020 Mar 6;19:278-292. doi: 10.1016/j.omtn.2019.11.012. PMID: 31855836
Protective effects of mirtazapine in mice lacking the Mbnl2 gene in forebrain glutamatergic neurons: Relevance for myotonic dystrophy 1. Ramon-Duaso C, Rodriguez-Morato J, Selma Soriano E, Fernandez-Aviles C, Artero Allepuz R, de la Torre R, Pozo O, Robledo P. Neuropharmacology. 2020 Jun 15;170:108030. doi: 10.1016/j.neuropharm.2020.108030. PMID: 32171677
Rabphilin involvement in filtration and molecular uptake in Drosophila nephrocytes suggests a similar role in human podocytes. Selma Soriano E, Llamusi Troisi M, Fernandez Costa J, Ozimski L, Artero Allepuz R, Redón Mas J. Disease Models & Mechanisms. 2020 Sep 21;13(9):dmm041509. doi: 10.1242/dmm.041509. PMID: 32680845
Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy. Cerro Herreros E, Gonzalez Martinez I, Moreno Cervera N, Overby S, Perez Alonso M, Llamusi Troisi M, Artero Allepuz R. Molecular therapy. Nucleic acids. 2020 Sep 4;21:837-849. doi: 10.1016/j.omtn.2020.07.021. PMID: 32805487
Projects
Title: Especialización en fenotipado y caracterización molecular de modelos biomédicos murinos
Funding body: Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital
Principal Investigator: Rubén Artero Allepuz
Duration: 2023 – 2024
Total budget: 44.812 €
Title: Desarrollo preclínico de gapmers contra una nueva diana terapéutica en Distrofia Miotónica
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Manuel Pérez Alonso
Duration: 2022 – 2023
Total budget: 127.600 €
Title: Del RNA tóxico a la medicina traslacional en Distrofia Miotónica (para la captación de recursos UE)
Funding body: Ministerio de Ciencia e Innovación
Principal Investigator: Rubén Artero Allepuz
Duration: 2022 – 2022
Total budget: 15.000 €
Title: Reposicionamiento de un fármaco para atrofia muscular espinal
Funding body: Agencia Valenciana de la Innovación-AVI Generalitat Valenciana
Principal Investigator: Rubén Artero Allepuz
Duration: 2021 – 2023
Total budget: 487.727 €
Title: Valorization of the repurposing of two drug candidates for spinal muscular atrophy
Funding body: Fundación Bancaria La Caixa
Principal Investigator: Rubén Artero Allepuz
Duration: 2021 – 2023
Total budget: 100.000 €
Title: miR-OA: Inhibidores de miRNAs como terapia en osteoartritis
Funding body: Universidad de Valencia – INCLIVA
Principal Investigator: Rubén Artero Allepuz, Carmen Carda Batalla
Duration: 2021 – 2022
Total budget: 19.000 €
Title: Implicaciones experimentales y clinicas del complejo proteico rabphilin-rab en daño renal en la diabetes mellitus tipo 2
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Josep Redón i Mas
Duration: 2020 – 2023
Total budget: 196.020 €
Title: Desarrollo preclínico de un fármaco innovador para distrofia miotónica
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Rubén Artero Allepuz
Duration: 2020 – 2022
Total budget: 111.100 €
Title: Uso de moduladores de microRNAs como terapias experimentales en distrofia miotónica de tipo 1
Funding body: Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital
Principal Investigator: Rubén Artero Allepuz
Duration: 2020 – 2023
Total budget: 193.051 €
Title: Desarrollo de una terapia innovadora contra la distrofia miotónica
Funding body: Precipita (Crowdfunding)
Principal Investigator: Rubén Artero Allepuz
Duration: 2020 – 2020
Total budget: 17.703 €
Title: Antisense RNA-therapeutics in Myotonic Dystrophy
Funding body: Fundación para la Innovación y Prospectiva en Salud en España (FIPSE)
Principal Investigator: Rubén Artero Allepuz, Beatriz Llamusí
Duration: 2019 – 2020
Total budget: 25.000 €
Title: Development of combinatorial therapies for SMA
Funding body: AFM Telethon
Principal Investigator: Rubén Artero Allepuz
Duration: 2019 – 2020
Total budget: 175000
Title: Desarrollo de un modelo en Drosophila de LGMD1F
Funding body: Asociación Conquistando Escalones
Principal Investigator: Rubén Artero Allepuz
Duration: 2019 – 2020
Total budget: 17.303 €
Title: Comprensión de las causas moleculares de la atrofia muscular en distrofia miotónica tipo 1
Funding body: Ministerio de Ciencia e Innovación
Principal Investigator: Rubén Artero Allepuz
Duration: 2019 – 2021
Total budget: 185.000 €
Title: TATAMI (TherApeutic TArgeting of MIrnas) therapeutic targeting of mbnl micrornas as innovative treatments for myotonic dystrophy
Funding body: Fundación Bancaria La Caixa
Principal Investigator: Rubén Artero Allepuz
Duration: 2018 – 2021
Total budget: 997.023 €
Title: COST: European Cooperation in Science and Technology, Delivery of Antisense RNA Therapeutics (DARTER)
Funding body: European Commission
Principal Investigator: Virginia Arechavala
Duration: 2018 – 2022
Total budget: 500.000 €
+ Info
Doctoral candidate: Sabater Arcís, María
Director(s): Artero Allepuz, Rubén; Bargiela Schönbrunn, Ariadna
Date of the defense: 01/04/2022
University: Universitat de València
Title: Proof of concept of therapeutic gene modulation of MBNL1/2 in myotonic dystrophy
Doctoral candidate: Overby, Sarah
Director(s): Artero Allepuz, Rubén
Date of the defense: 21/01/2022
University: Universitat de València
Title: Mejora de la actividad de un hexapéptido anti-dm1 y análisis de las relaciones entre estructura y actividad de hexapéptidos de secuencia similar
Doctoral candidate: Rapisarda, Anna Serafina Rapisarda
Director(s): Artero Allepuz, Ruben Darío
Date of the defense: 31/01/2020
University: Universitat de València
Title: Papel del complejo de proteínas rab-rabphilin en un modelo de daño renal en drosophila
Doctoral candidate: Selma Soriano, Estela
Director(s): Artero Allepuz, Ruben Darío
Date of the defense: 16/01/2020
University: Universitat de València